Cutler Group LP Glycomimetics Inc Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 07, 2020	SELL	$1.83 - $5.41 $732 - $2,164	-400 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$4.03 - $6.5 $403 - $650	100 Added 33.33%	400 $1,000
Q3 2019 Oct 28, 2019	SELL	$2.8 - $12.85 $1,959 - $8,995	-700 Reduced 70.0%	300 $0
Q2 2019 Aug 09, 2019	SELL	$10.6 - $13.12 $31,800 - $39,360	-3,000 Reduced 75.0%	1,000 $2,000
Q1 2019 May 10, 2019	BUY	$9.96 - $13.44 $39,840 - $53,760	4,000 New	4,000 $3,000
Q4 2018 Feb 05, 2019	SELL	$8.47 - $14.71 $76,230 - $132,390	-9,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$13.7 - $17.12 $54,800 - $68,480	4,000 Added 80.0%	9,000 $10,000
Q2 2018 Aug 10, 2018	SELL	$14.63 - $19.19 $279,433 - $366,529	-19,100 Reduced 79.25%	5,000 $2,000
Q1 2018 May 11, 2018	SELL	$16.06 - $25.35 $56,209 - $88,725	-3,500 Reduced 12.68%	24,100 $19,000
Q4 2017 Jan 17, 2018	BUY	$10.51 - $17.22 $289,025 - $473,549	27,500 Added 27500.0%	27,600 $121,000
Q3 2017 Oct 17, 2017	BUY	$10.14 - $14.85 $1,014 - $1,485	100	100 $0

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.